We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PHIN:NYSEPHINIA Inc. Analysis

Data as of 2026-05-29 - not real-time

$77.26

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

PHINIA Inc. is trading at $77.26, comfortably above its 20‑day and 50‑day SMAs ($76.67 and $72.71) and well above the 200‑day SMA ($63.99), indicating a bullish price structure despite a bearish MACD histogram. Support sits near $71.21 while resistance is around $80.93, leaving room for upside, and the DCF‑derived fair value of $85.60 suggests roughly a 14‑% discount to intrinsic value. Volume is trending lower, and the 30‑day volatility of 34% combined with a beta above 1 points to heightened price swings, but the market sentiment is in the “Extreme Greed” zone (Fear‑Greed Index 94).
Fundamentally, PHIN posted 10.3% revenue growth to $3.56 B and an adjusted EBITDA of $488 M, with forward EPS projected at $6.76, driving a forward P/E of 11.4. The company maintains a modest dividend yield of 1.55% with a 31% payout ratio, and free cash flow of $190 M supports dividend sustainability. Recent earnings beat estimates and an upgrade to Zacks Rank 1 Strong Buy reinforce the growth narrative, while a debt‑to‑equity of 67% and a max drawdown of ~21% temper enthusiasm.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Price above short‑term moving averages with support at $71.21
  • Technical bullish trend despite bearish MACD signal
  • Current discount to DCF fair value (~14%)

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Revenue growth of 10% and forward EPS upside
  • Analyst consensus targets ($88‑$92) above current price
  • Sustainable dividend and improving cash flow generation

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervalued relative to intrinsic DCF estimate
  • Strong market position in fuel‑system and aftermarket segments
  • Resilient earnings outlook despite cyclical sector exposure

Key Metrics & Analysis

Financial Health

Revenue Growth10.30%
Profit Margin3.96%
P/E Ratio21.6
ROE9.14%
ROA5.43%
Debt/Equity67.08
P/B Ratio1.8
Op. Cash Flow$325.0M
Free Cash Flow$189.8M

Technical Analysis

TrendBullish
RSI55.9
Support$71.21
Resistance$80.93
MA 20$76.67
MA 50$72.71
MA 200$64.00
MACDBearish
VolumeDecreasing
Fear & Greed Index94.07

Valuation

Fair Value$85.60
Target Price$88.75
Upside/Downside14.87%
GradeUndervalued
TypeBlend
Dividend Yield1.55%

Risk Assessment

Beta1.17
Volatility34.47%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.